The question is more urgent as over-the-counter continuous glucose monitoring devices become more widely available.

Griffin presented several tools such as magnifiers, voice-enabled glucose meters, and CGMs integrated with voice assistants ... 5 where legally blind patients who used a Dexcom G6 CGM combined with ...

Dexcom has rounded up its celebrity spokespeople for World Diabetes Day, putting singer Nick Jonas at the center of a campaign intended to help people change their perception of what they can achieve.

Its products, including the Dexcom G6 and G7, aim to help people with diabetes manage their blood glucose levels through real-time data transmission and monitoring. Shares of the medical device ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices ...

Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices Commodities ...

Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S. declined year over year despite overall sales coming in slightly ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus ...